New generation dopaminergic agents 4. Exploiting the 2-methyl chroman scaffold. Synthesis and evaluation of two novel series of 2-(aminomethyl)- 3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indol-8-one derivatives

Tetrahedron

Volumn 54, Issue 25, 1998, Pages 7081-7108

  Mewshaw, Richard E ^a   Marquis, Karen L ^a   Shi, Xiaojie ^a   McGaughey, Georgia ^a   Stack, Gary ^a   Webb, Michael B ^a   Abou Gharbia, Magid ^a   Wasik, Theodore ^a   Scerni, Rosemary ^a   Spangler, Taylor ^a   Brennan, Julie A ^a   Mazandarani, Hossein ^a   Coupet, Joseph ^a   Andree, Terrance H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MOLECULAR MODEL; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 0032543519     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(98)00349-4     Document Type: Article

References (30)

1. [1] Derwin R, Taylor D. CNS Drugs 1996;6:71-82.
2. [2] Uitti RJ, Ahlskog JE. CNS Drugs 1996, 5, 369-388.
3. [3] Kaiser C, Jain T. Med. Res. Rev. 1985; 5:145-229.
4. [4] Freeman HS, McDermed JD. Interactions of chiral agonists with dopamine receptors. In: Crieghton, AM, Turner, S, editors. Chemical Regulation of Biological Mechanisms. London: Royal Society of Chemistry, 1982:154-165.
5. [5] McDermed JD, Freeman HS, Ferris RM. In: Usdin E, Kopin IJ, Barchas J, editors. Catacholamines: Basic and Clinical Frontiers, Proc. Int. Catecholamine Symp., 4th (1979). New York: Pergamon Press, 1979:1:568-570.
6. [6] Cannon JE. Progress in Drug Research (Jucker E, Ed) Birkauser Verlag, Basel, Switzerland, 1985;29:303-413.
7. [7] Cannon JG. Adv. Neurol. 1975;9:177-183.
8. [8] Seiler MP, Markstein MD, Walkinshaw MD, Boelsterli JJ. Mol. Pharm. 1989;35:643-651.
9. [9] Seiler MP, Floersheim P, Markstein R, Widmer A. J. Med. Chem. 1993;36:977-984.
10. [10] Liljefors T, Wikstrom H. J. Med. Chem. 1986;29:1896-1904.
11. [11] Liljefors T, Bogeso KP, Hyttel J, Wikstrom H, Svensson K, Carlsson A. J. Med. Chem. 1990;33:1015-1022.
12. [12] Wise LD, Jaen JC. Design of orally active dopamine autoreceptor agonists. In: Kozikowski AP. editor. Drug Design in Neuroscience. New York: Raven Press, Ltd., 1993:119-148.
13. [13] Mewshaw RE, Kavanagh J, Stack G, Marquis K, Shi X, Kagan MZ, Webb MB, Katz AH, Park A, Kang YH, Abou-Gharbia M, Wasik T, Cortes-Burgos L, Scerni R, Spangler T, Brennan JA, Piesla M, Mazandarani H, Coupet J, Andree TH. J. Med. Chem. 1997;40:4235-4256.
14. [14] Mewshaw RE, Husbands M, Gildersleeve ES, Webb MB, Shi X, Mazandarani H, Cockett MI, Ochalski R, Brennan JA, Abou-Gharbia M, Marquis K, McGaughey GB, Coupet J, Andree TH. Bioorg. Med. Chem. Lett. 1998;8:295-300.
15. [15] Mewshaw RE, Shi X, Mazandarani H, Coupet JT, McGaughey GB, Andree TH. Med. Chem. Res. 1997;7:429-435.
16. [16] Cannon, JG. Adv. Biosci. 1979;20:87-94.
17. [17] Cannon JG, Demopoulos BJ, Long JP, Flynn JR, Sharabi FM. J. Med. Chem. 1981;24:238-240.
18. [18] Asselin AA, Humber LG, Voith K, Metcalf G. J. Med Chem. 1986;29:648-654.
19. [19] Stjernlof P, Elebring T, Nilsson J, Andersson B, Lagerkvist S, Svensson K, Ekman A, Carlsson A, Wekstrom H. J. Med. Chem. 1994;37:3263-3273.
20. [20] Huffman WF, Hall RF, Grant JA, Wilson JW, Hieble JP, Hahn RA. J. Med. Chem. 1983;26:933-935.
21. [21] DeMarinis RM, Hieble JP. Drugs of the Future, 1989;14:781-797.
22. [22] Chenard BL, Butler TW, Shalaby A, Prochniak MA, Koe BK, Fox CB. Bioorg. Med. Chem. Letters 1993;3:91-94.
23. [23] Nichols DE, Cassady JM, Persons PE, Yeung MC, Clemens JA. J. Med. Chem. 1989, 32, 2128-2134.
24. [24] Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. Mol. Pharm. 1992;42:432-438.
25. [25] Ennis MD, Baze ME, Smith MW, Lawson CF, McCall RB, Lahti RA, Piercey MF. J. Med. Chem. 1992;35:3058-3066.
26. [25] Clarke BS, Jakubovic A, Fibiger H. Psychopharmacology 1998;96:511-520.
27. [25] Silverman PB, Ho BT. Nature 1981;294:475-476.
28. [28] Stoessl AJ, Dourish CT, Iverson SD. Psychopharmacology 1997;93:336-342.
29. [29] Ungerstedt U. Acta Physiol. Scand. Suppl. 1971;367:69-93.
30. [30] Sheldrick GM. SHELXL-93, Program for refinement of crystal structures, University of Gottingen, 1993.